ALLY

ALLY

ALLY

Market Cap: $12.97B

Letters With This Ticker

Quarter Letter Date Fund Name QTD YTD Tickers Keywords/Themes Theme Commentary Pitches Letter
2025 Q3 Sep 30, 2025 Antipodes Global Fund - - 000660.KS, 0700.HK, 300750.SZ, 3690.HK, 4063.T, 6367.T, 6702.T, AAPL, ALLY, ASAI3.SA, AVGO, COF, EAT, GMED, Gold, GOOGL, MRK, MSFT, MU, NG.L, NVDA, PCOR, TSLA, UBS AI, China, Electric Vehicles, global, gold, healthcare, semiconductors, technology
2026 Q1 Apr 29, 2026 Oldfield Partners Overstone Global Large Cap 4.7% 4.7% 005930 KS, ALLY, E, EZJ.L, LUV, MRK.DE Airlines, defense, Geopolitical, global, Memory, oil, value ALLY
MRK.DE
2022 Q3 Jul 10, 2022 Moon Capital Management 0.0% 23.0% ALLY, SOBKY, SYF -
2023 Q4 Jan 26, 2024 Moon Capital Management 0.0% 23.0% ALLY, BN, FI, FRFHF, GRBK, KKR, MBIN, META Banking, contrarian, financials, Homebuilders, Quality, value MBIN

Pitches With This Ticker

Date Pitch Type Author Company Industry Sub Industry Bull / Bear Stock Exchange Keywords Action
May 6, 2026 Fund Letters Oldfield Partners Overstone Global Large Cap Ally Financial Inc Credit Services Consumer Finance Bull New York Stock Exchange Auto finance, consumer finance, Deposit-Funded, digital banking, Equity, net interest margin, transformation, US, Value
Apr 28, 2026 Fund Letters Madison Sustainable Equity Fund Eli Lilly and Company Health Care Pharmaceuticals Bull NYSE Alzheimer’s, Biotech, Diabetes, drug approval, healthcare, Obesity, pharmaceuticals
Apr 28, 2026 Fund Letters Aristotle Core Equity Fund Eli Lilly & Company Health Care Pharmaceuticals Bull NYSE Biotech, Diabetes, GLP-1, growth, Mounjaro, Obesity, pharmaceuticals, pipeline
Apr 28, 2026 Fund Letters Aristotle Atlantic Core Equity Strategy Eli Lilly & Company Health Care Pharmaceuticals Bull NYSE Biotech, Diabetes, GLP-1, Immunology, Metabolic Disorders, Obesity, Oncology, pharmaceuticals, pipeline
Apr 28, 2026 Fund Letters RiverPark Large Growth Eli Lilly and Company Health Care Pharmaceuticals Bull NYSE Alzheimer’s, Biotech, Diabetes, Franchise Products, Global, Obesity, Oncology, pharmaceuticals, pipeline
Apr 28, 2026 Fund Letters Tall Oak Capital Advisors Eli Lilly & Co Health Care Pharmaceuticals Bull New York Stock Exchange biotechnology, Diabetes, GLP-1, healthcare innovation, Multi-year Theme, obesity treatment, pharmaceuticals, Thematic investing, tirzepatide, Weight loss
Apr 28, 2026 Fund Letters WestEnd Capital Eli Lilly & Co. Pharmaceuticals, Biotechnology & Life Sciences Pharmaceuticals Bull NYSE biotechnology, Clinical trials, Diabetes, GLP-1, growth, healthcare, Obesity, pharmaceuticals, R&D
Apr 28, 2026 Fund Letters Nixon Capital Eli Lilly & Co. Pharmaceuticals, Biotechnology & Life Sciences Pharmaceuticals Bull NYSE biotechnology, Clinical trials, Diabetes, GLP-1, growth, healthcare, Obesity, pharmaceuticals
Apr 28, 2026 Fund Letters Madison Sustainable Equity Fund Eli Lilly & Co Health Care Pharmaceuticals Bull NYSE Alzheimer’s, Diabetes, FDA approval, GLP-1, Obesity, pharmaceuticals, pipeline
Apr 27, 2026 Fund Letters Fortress - Caribbean Growth Fund Eli Lilly & Co. Pharmaceuticals, Biotechnology & Life Sciences Pharmaceuticals Bull NYSE Biotech, Diabetes, GLP-1, growth, Obesity, pharmaceuticals, R&D
Apr 27, 2026 Fund Letters Madison Sustainable Equity Fund Eli Lilly & Co Health Care Pharmaceuticals Bull NYSE Alzheimer’s, Diabetes, GLP-1, Mounjaro, Obesity, pharmaceuticals, pipeline
Apr 27, 2026 Fund Letters ClearBridge Investments All Cap Growth Eli Lilly and Company Health Care Pharmaceuticals Bull NYSE Alzheimer’s, blockbuster drug, Clinical trials, Diabetes, Mounjaro, Obesity, pharmaceuticals
Apr 27, 2026 Fund Letters LVS Advisory - Growth Eli Lilly & Co. Pharmaceuticals, Biotechnology & Life Sciences Pharmaceuticals Bull NYSE Biotech, Diabetes, GLP-1, growth, Obesity, pharmaceuticals, R&D
Apr 27, 2026 Fund Letters Airlie Small Companies Fund Eli Lilly & Co. Pharmaceuticals, Biotechnology & Life Sciences Pharmaceuticals Bull NYSE Biotech, Diabetes, GLP-1, growth, healthcare, Obesity, pharmaceuticals
Jan 22, 2026 Seeking Alpha Seeking Alpha Ally Financial Inc. Financial Services Consumer Finance Neutral New York Stock Exchange Ally Financial, Auto lending, capital adequacy, consumer finance, Credit risk, economic downturn, financial services, net interest margin, Share Buyback, stock valuation
Aug 7, 2025 Seeking Alpha Seeking Profits Ally Financial Financials Credit Services Neutral NYSE —
Aug 7, 2025 Seeking Alpha Albert Anthony Ally Financial Inc. Financials Credit Services Bull NYSE —

BSD Shareholders of ALLY

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025
Manager Name Fund Name Fund AUM Invested Value Portfolio Weight Shares Owned Shares Bought / Sold During Quarter % Bought / Sold During Quarter % of Shares Outstanding Owned
Anthony Bozza Lakewood Capital Management $1.5B $47.0M 3.11% 1,036,809 +720,000 +227.27% 0.3621%
Donald G. Smith Donald Smith & Co. $5.3B $123.3M 2.31% 2,722,909 +163,046 +6.37% 0.9509%
Sarah Ketterer Causeway Capital Management LLC $7.3B $27.2M 0.37% 600,850 -35,319 -5.55% 0.2098%
David Einhorn Greenlight Capital Inc $9.9B $31.2M 0.32% 866,182 +0 +0.00% 0.3133%
Paul Tudor Jones Tudor Investment Corp $53.4B $412,909 0.00% 9,117 -183,200 -88.42% 0.0032%
Steven A. Cohen Point72 Asset Management $86.8B $15.8M 0.02% 349,659 -560,873 -61.60% 0.1221%
Chris Rokos Rokos Capital Management $9.9B $31.2M 0.32% 866,182 +0 +0.00% 0.3133%
Ray Dalio Bridgewater Associates $27.4B $7.2M 0.03% 159,445 +106,852 +203.17% 0.0557%
Dmitry Balyasny Balyasny Asset Management $76.6B $379,349 0.00% 8,376 -17,945 -68.18% 0.0029%
Israel Englander Millennium Management LLC $233.2B $14.0M 0.01% 309,640 -1,273,077 -80.44% 0.1081%
David Siegel & John Overdeck Two Sigma Investments $67.5B $82.0M 0.12% 1,811,076 +591,410 +48.49% 0.6325%
Cliff Asness AQR Capital Management $190.6B $18.7M 0.01% 412,902 +40,417 +10.85% 0.1442%
Bruce Kovner Caxton Associates $3.2B $915,374 0.03% 25,420 -1,716 -6.32% 0.0071%
Louis Bacon Moore Capital Management $6.8B $67.6M 1.00% 1,491,829 -500,000 -25.10% 0.5210%
Matthew Barrett Glendon Capital Management $1.7B $94.3M 5.62% 2,083,219 -255,114 -10.91% 0.7275%
Warren Buffett Berkshire Hathaway $274.2B $1.3B 0.48% 29,000,000 +29,000,000 +100.00% 10.1273%
George Soros Soros Fund Management $6.8B $76.4M 1.13% 1,687,493 +949,793 +128.75% 0.5893%
Richard Kayne & John Anderson Kayne Anderson Rudnick Investment Management $37.3B $7,857 0.00% 173 +0 +0.00% 0.0001%

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

join for free
buysidedigest hedge fund letters for investors

Follow Us On: